Foundation Medicine and Joint Collaborators to Present 12 Abstracts at the ESMO Congress 2026

Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced the acceptance of 12 abstracts for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27, 2026, in Madrid, Spain. These presentations cover key topics such as MTAP loss, the clinical impact of clonal hematopoiesis (CH), and the expanded utility of circulating tumor DNA (ctDNA) tumor fraction.

In addition to 10 poster presentations, Foundation Medicine’s research will be featured in two Rapid Oral Sessions:

• 2218RO – Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)
  
  Friday, October 23 at 13:00 CEST in Bilbao Auditorium – Hall 3

• 2219RO – Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)
  
  Friday, October 23 at 13:00 CEST in Bilbao Auditorium – Hall 3

Foundation Medicine will also host a series of expert-led booth talks in its booth 1030 in Hall 10:

• Saturday, October 24
  • 13:00 – 13:15 CEST – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection

  • 13:25 – 13:40 CEST – Breaking the Sensitivity Floor: The Science of Ultra-Sensitive MRD

  • 13:50 – 14:05 CEST – Detect MTAP Loss More Often in Your Clinical Trials: Don’t Miss the Signal

  • 14:15 – 14:30 CEST – Don’t Miss Fusions and Complex Variants with FoundationOne^®RNA

• Sunday, October 25
  • 13:00 – 13:15 CET – Translating Ultra-Sensitive MRD to Clinical Practice: Detection and Monitoring of ctDNA Using Structural Variants

  • 13:30 – 13:45 CET – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection

  • 14:00 – 14:15 CET – Redefining the Standard in MRD: Structural Variants & Digital PCR for Ultra Sensitivity & High Specificity

• Monday, October 26
  • 13:00 – 13:15 CET- The Role of Longitudinal ctDNA Testing in Early and Advanced Stage Cancer

  • 13:30 – 13:45 CET – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection

  • 14:00 – 14:15 CET – HRD Signature Without Limits: Go Beyond Ovarian

To learn more, visit Foundation Medicine in person at booth 1030 in Hall 10 or book a meeting at https://www.foundationmedicine.com/event/esmo-congress-2026.

Full List of Foundation Medicine’s Abstracts at ESMO Congress 2026

About Foundation Medicine

Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com and follow us on LinkedIn, X, YouTube, Facebook, Instagram and BlueSky.

About FoundationOne^®CDx

FoundationOne^®CDx is for prescription use only and is an FDA-approved qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy which may pose a risk. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.

About FoundationOne^®Liquid CDx

FoundationOne^®Liquid CDx is for prescription use only and is an FDA-approved qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes, rearrangements in 8 genes and copy number alterations in 3 genes, and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. When considering eligibility for ROZLYTREK^® based on the detection of NTRK1/2/3 and ROS1 fusions, or for TEPMETKO^® based on the detection of MET SNVs and indels that lead to MET exon 14 skipping, testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.

About FoundationOne^®RNA

FoundationOne^®RNA is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne RNA has not been cleared or approved by the U.S. Food and Drug Administration. FoundationOne RNA is a test for solid tumors which utilizes RNA sequencing to interrogate 318 cancer-related genes to capture gene fusions and rearrangements. A negative result does not rule out the presence of an alteration. Genomic findings are not prescriptive or conclusive for labeled use of any specific therapeutic product.

About FoundationOne^®Monitor

FoundationOne^®Monitor is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. This test has not been cleared or approved by the U.S. Food and Drug Administration. FoundationOne Monitor is a test for patients with solid malignant neoplasms that detects and longitudinally tracks circulating tumor DNA (ctDNA), reported as ctDNA tumor fraction (a determination of the amount of ctDNA as a fraction of total cell free DNA in a blood sample) as a biomarker for tumor content in the blood. Treatment decisions are the responsibility of the treating physician. ctDNA tumor fraction determination sensitivity may be limited if blood collection occurs within two weeks of surgery. ctDNA not detected status does not definitively indicate the absence of cancer and declining ctDNA tumor fraction does not necessarily indicate a response to therapy. This test is not designed to detect or report germline variation, nor does it infer hereditary cancer risk for a patient. This test is expected to have limited sensitivity in some cancer types due to limited ctDNA shed.

Foundation Medicine and FoundationOne^® are registered trademarks of Foundation Medicine, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021800190/en/

Media gallery